Connect Biopharma is a San Diego company developing rademikibart, an antibody in trials for asthma and COPD. CNTB reports earnings on Wed, Nov 11, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (4 buy, 0 hold, 0 sell).
Prices, price targets and earnings estimates for CNTB are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
No whale options trades in CNTB in the last 90 days.
Total alerts
0
Bullish
0
0%
Bearish
0
0%
Date span
—
Loading…
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CNTB is in one of them and how their past CNTB trades turned out.
Connect Biopharma is a biopharmaceutical company based in San Diego, California. It is developing rademikibart, an antibody designed to block a receptor involved in airway inflammation. The drug is in clinical trials for sudden worsening episodes of asthma and chronic obstructive pulmonary disease (COPD), which are lung conditions that make breathing difficult. The company's target market is patients with these diseases and the hospitals that treat them, although the drug is not yet approved for sale.
